Alpha 1 Antitrypsin Deficiency Treatment Market Report

China Alpha 1 Antitrypsin Deficiency Treatment Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 25, 2022
  • PAGES：211
  • REPORT CODE：GMM1176107
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.

    This report offers an overview of the market trends, drivers, and barriers with respect to the China Alpha 1 Antitrypsin Deficiency Treatment market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Alpha 1 Antitrypsin Deficiency Treatment market. Detailed analysis of key players, along with key growth strategies adopted by Alpha 1 Antitrypsin Deficiency Treatment industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Kamada Ltd

    • Chiesi Pharmaceuticals

    • ProMetic Life Sciences

    • GlaxoSmithKline

    • Grifols

    • ProBioGen

    • Biogen

    • Baxalta

    • AstraZeneca

    • Shire

    • Abeona Therapeutics

    • Boehringer Ingelheim

    • CSL Behring

    • Baxter

    • Applied Genetic Technologies

    • Arrowhead Research Corporation

    • Teva Pharmaceutical Industries

    • Curaxys

    • Pfizer

    • LFB Biomedicaments

    By Type:

    • Augmentation Therapy

    • Bronchodilators

    • Corticosteroids

    • Oxygen Therapy

    By End-User:

    • Hospitals

    • Specialty Clinics

    • Pharmacies

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Alpha 1 Antitrypsin Deficiency Treatment Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Augmentation Therapy from 2016 to 2027

    • 1.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Bronchodilators from 2016 to 2027

    • 1.3.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Corticosteroids from 2016 to 2027

    • 1.3.4 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Oxygen Therapy from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Hospitals from 2016 to 2027

    • 1.4.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

    • 1.4.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Pharmacies from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Alpha 1 Antitrypsin Deficiency Treatment Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Alpha 1 Antitrypsin Deficiency Treatment by Major Types

    • 3.4.1 Market Size and Growth Rate of Augmentation Therapy

    • 3.4.2 Market Size and Growth Rate of Bronchodilators

    • 3.4.3 Market Size and Growth Rate of Corticosteroids

    • 3.4.4 Market Size and Growth Rate of Oxygen Therapy

    4 Segmentation of Alpha 1 Antitrypsin Deficiency Treatment Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Alpha 1 Antitrypsin Deficiency Treatment by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Alpha 1 Antitrypsin Deficiency Treatment in Hospitals

    • 4.4.2 Market Size and Growth Rate of Alpha 1 Antitrypsin Deficiency Treatment in Specialty Clinics

    • 4.4.3 Market Size and Growth Rate of Alpha 1 Antitrypsin Deficiency Treatment in Pharmacies

    5 Market Analysis by Regions

    • 5.1 China Alpha 1 Antitrypsin Deficiency Treatment Production Analysis by Regions

    • 5.2 China Alpha 1 Antitrypsin Deficiency Treatment Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 6.1 North China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 6.2 North China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    7 Central China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 7.1 Central China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 7.2 Central China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    8 South China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 8.1 South China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 8.2 South China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    9 East China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 9.1 East China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 9.2 East China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    10 Northeast China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 10.1 Northeast China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 10.2 Northeast China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    11 Southwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 11.1 Southwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 11.2 Southwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    12 Northwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis

    • 12.1 Northwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major Types

    • 12.2 Northwest China Alpha 1 Antitrypsin Deficiency Treatment Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Kamada Ltd

      • 13.1.1 Kamada Ltd Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Chiesi Pharmaceuticals

      • 13.2.1 Chiesi Pharmaceuticals Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 ProMetic Life Sciences

      • 13.3.1 ProMetic Life Sciences Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 GlaxoSmithKline

      • 13.4.1 GlaxoSmithKline Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 Grifols

      • 13.5.1 Grifols Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 ProBioGen

      • 13.6.1 ProBioGen Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 Biogen

      • 13.7.1 Biogen Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 Baxalta

      • 13.8.1 Baxalta Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    • 13.9 AstraZeneca

      • 13.9.1 AstraZeneca Company Profile and Recent Development

      • 13.9.2 Market Performance

      • 13.9.3 Product and Service Introduction

    • 13.10 Shire

      • 13.10.1 Shire Company Profile and Recent Development

      • 13.10.2 Market Performance

      • 13.10.3 Product and Service Introduction

    • 13.11 Abeona Therapeutics

      • 13.11.1 Abeona Therapeutics Company Profile and Recent Development

      • 13.11.2 Market Performance

      • 13.11.3 Product and Service Introduction

    • 13.12 Boehringer Ingelheim

      • 13.12.1 Boehringer Ingelheim Company Profile and Recent Development

      • 13.12.2 Market Performance

      • 13.12.3 Product and Service Introduction

    • 13.13 CSL Behring

      • 13.13.1 CSL Behring Company Profile and Recent Development

      • 13.13.2 Market Performance

      • 13.13.3 Product and Service Introduction

    • 13.14 Baxter

      • 13.14.1 Baxter Company Profile and Recent Development

      • 13.14.2 Market Performance

      • 13.14.3 Product and Service Introduction

    • 13.15 Applied Genetic Technologies

      • 13.15.1 Applied Genetic Technologies Company Profile and Recent Development

      • 13.15.2 Market Performance

      • 13.15.3 Product and Service Introduction

    • 13.16 Arrowhead Research Corporation

      • 13.16.1 Arrowhead Research Corporation Company Profile and Recent Development

      • 13.16.2 Market Performance

      • 13.16.3 Product and Service Introduction

    • 13.17 Teva Pharmaceutical Industries

      • 13.17.1 Teva Pharmaceutical Industries Company Profile and Recent Development

      • 13.17.2 Market Performance

      • 13.17.3 Product and Service Introduction

    • 13.18 Curaxys

      • 13.18.1 Curaxys Company Profile and Recent Development

      • 13.18.2 Market Performance

      • 13.18.3 Product and Service Introduction

    • 13.19 Pfizer

      • 13.19.1 Pfizer Company Profile and Recent Development

      • 13.19.2 Market Performance

      • 13.19.3 Product and Service Introduction

    • 13.20 LFB Biomedicaments

      • 13.20.1 LFB Biomedicaments Company Profile and Recent Development

      • 13.20.2 Market Performance

      • 13.20.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Augmentation Therapy from 2016 to 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Bronchodilators from 2016 to 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Corticosteroids from 2016 to 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Oxygen Therapy from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Hospitals from 2016 to 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Growth Rate of Pharmacies from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Alpha 1 Antitrypsin Deficiency Treatment Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Alpha 1 Antitrypsin Deficiency Treatment

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Alpha 1 Antitrypsin Deficiency Treatment by Different Types from 2016 to 2027

    • Table Consumption Share of Alpha 1 Antitrypsin Deficiency Treatment by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Augmentation Therapy

    • Figure Market Size and Growth Rate of Bronchodilators

    • Figure Market Size and Growth Rate of Corticosteroids

    • Figure Market Size and Growth Rate of Oxygen Therapy

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Alpha 1 Antitrypsin Deficiency Treatment by Different End-Users from 2016 to 2027

    • Table Consumption Share of Alpha 1 Antitrypsin Deficiency Treatment by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospitals

    • Figure Market Size and Growth Rate of Specialty Clinics

    • Figure Market Size and Growth Rate of Pharmacies

    • Table China Alpha 1 Antitrypsin Deficiency Treatment Production by Regions

    • Table China Alpha 1 Antitrypsin Deficiency Treatment Production Share by Regions

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Production Share by Regions in 2016

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Production Share by Regions in 2021

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Production Share by Regions in 2027

    • Table China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions

    • Table China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Regions

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Regions in 2016

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Regions in 2021

    • Figure China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Regions in 2027

    • Table North China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table North China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure North China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure Central China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table South China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table South China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure South China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table East China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table East China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure East China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure Northeast China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure Southwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption by Types from 2016 to 2027

    • Table Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2016

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2021

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by Types in 2027

    • Table Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption by End-Users from 2016 to 2027

    • Table Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2016

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2021

    • Figure Northwest China Alpha 1 Antitrypsin Deficiency Treatment Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Kamada Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kamada Ltd

    • Figure Sales and Growth Rate Analysis of Kamada Ltd

    • Figure Revenue and Market Share Analysis of Kamada Ltd

    • Table Product and Service Introduction of Kamada Ltd

    • Table Company Profile and Development Status of Chiesi Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Chiesi Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Chiesi Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Chiesi Pharmaceuticals

    • Table Product and Service Introduction of Chiesi Pharmaceuticals

    • Table Company Profile and Development Status of ProMetic Life Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ProMetic Life Sciences

    • Figure Sales and Growth Rate Analysis of ProMetic Life Sciences

    • Figure Revenue and Market Share Analysis of ProMetic Life Sciences

    • Table Product and Service Introduction of ProMetic Life Sciences

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Grifols

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Grifols

    • Figure Sales and Growth Rate Analysis of Grifols

    • Figure Revenue and Market Share Analysis of Grifols

    • Table Product and Service Introduction of Grifols

    • Table Company Profile and Development Status of ProBioGen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ProBioGen

    • Figure Sales and Growth Rate Analysis of ProBioGen

    • Figure Revenue and Market Share Analysis of ProBioGen

    • Table Product and Service Introduction of ProBioGen

    • Table Company Profile and Development Status of Biogen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biogen

    • Figure Sales and Growth Rate Analysis of Biogen

    • Figure Revenue and Market Share Analysis of Biogen

    • Table Product and Service Introduction of Biogen

    • Table Company Profile and Development Status of Baxalta

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Baxalta

    • Figure Sales and Growth Rate Analysis of Baxalta

    • Figure Revenue and Market Share Analysis of Baxalta

    • Table Product and Service Introduction of Baxalta

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of Shire

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shire

    • Figure Sales and Growth Rate Analysis of Shire

    • Figure Revenue and Market Share Analysis of Shire

    • Table Product and Service Introduction of Shire

    • Table Company Profile and Development Status of Abeona Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abeona Therapeutics

    • Figure Sales and Growth Rate Analysis of Abeona Therapeutics

    • Figure Revenue and Market Share Analysis of Abeona Therapeutics

    • Table Product and Service Introduction of Abeona Therapeutics

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of CSL Behring

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of CSL Behring

    • Figure Sales and Growth Rate Analysis of CSL Behring

    • Figure Revenue and Market Share Analysis of CSL Behring

    • Table Product and Service Introduction of CSL Behring

    • Table Company Profile and Development Status of Baxter

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Baxter

    • Figure Sales and Growth Rate Analysis of Baxter

    • Figure Revenue and Market Share Analysis of Baxter

    • Table Product and Service Introduction of Baxter

    • Table Company Profile and Development Status of Applied Genetic Technologies

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Applied Genetic Technologies

    • Figure Sales and Growth Rate Analysis of Applied Genetic Technologies

    • Figure Revenue and Market Share Analysis of Applied Genetic Technologies

    • Table Product and Service Introduction of Applied Genetic Technologies

    • Table Company Profile and Development Status of Arrowhead Research Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arrowhead Research Corporation

    • Figure Sales and Growth Rate Analysis of Arrowhead Research Corporation

    • Figure Revenue and Market Share Analysis of Arrowhead Research Corporation

    • Table Product and Service Introduction of Arrowhead Research Corporation

    • Table Company Profile and Development Status of Teva Pharmaceutical Industries

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva Pharmaceutical Industries

    • Figure Sales and Growth Rate Analysis of Teva Pharmaceutical Industries

    • Figure Revenue and Market Share Analysis of Teva Pharmaceutical Industries

    • Table Product and Service Introduction of Teva Pharmaceutical Industries

    • Table Company Profile and Development Status of Curaxys

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Curaxys

    • Figure Sales and Growth Rate Analysis of Curaxys

    • Figure Revenue and Market Share Analysis of Curaxys

    • Table Product and Service Introduction of Curaxys

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of LFB Biomedicaments

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of LFB Biomedicaments

    • Figure Sales and Growth Rate Analysis of LFB Biomedicaments

    • Figure Revenue and Market Share Analysis of LFB Biomedicaments

    • Table Product and Service Introduction of LFB Biomedicaments


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US